Substance / Medication

Ingenol mebutate

Overview

Active Ingredient
ingenol mebutate
RxNorm CUI
1242806

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

40 trials linked to this intervention

40
Total Trials
6
Recruiting
13
With Results

Research Evidence

Published studies and systematic reviews

Sort:
Ingenol Mebutate Gel 0.05% in the Treatment of Anogenital Warts: A Prospective Controlled Trial Comparing It With Topical Podophyllin Solution 25.
Shahidi Dadras Mohammad, Bizaval Zeinab, Hoormand Mahmood et al. · Sex Transm Dis · 2020
PMID: 32149954RCT
Ingenol mebutate gel for the treatment of molluscum contagiosum: An open-label comparative pilot study.
Shin Kihyuk, Bae Kyung-Nam, Kim Hoon-Soo et al. · J Am Acad Dermatol · 2020
PMID: 31499155RCT
Characterisation of the inflammatory response triggered by topical ingenol mebutate 0.05% gel in basal cell carcinoma.
García-de-la-Fuente Mª Reyes, Santacana Maria, Verdaguer Joan et al. · Australas J Dermatol · 2020
PMID: 31944277RCT
Monitoring sequential treatment of actinic keratosis using post-processed images: Ingenol mebutate and cryosurgery.
Pasquali Paola, Segurado-Miravalles Gonzalo, Baldi Alfonso et al. · Photodermatol Photoimmunol Photomed · 2019
PMID: 30815968RCT
Quality of life in treatment of AK: Treatment burden of ingenol mebutate gel is small and short lasting.
Hanke William C, Norlin Jenny M, Mark Knudsen Kim et al. · J Dermatolog Treat · 2016
PMID: 27052110RCT
Randomized, double-blind, double-dummy, vehicle-controlled study of ingenol mebutate gel 0.025% and 0.05% for actinic keratosis.
Anderson Lawrence, Schmieder George J, Werschler W Philip et al. · J Am Acad Dermatol · 2009
PMID: 19467365RCT

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Ingenol mebutate (substance)
SNOMED CT
710279008
UMLS CUI
C2825682
RxNorm CUI
1242806

Clinical Data

This intervention maps to 1 entities in the Ltrl knowledge graph.

1
Conditions
0
Biomarkers
0
Specialists
0
Symptoms
40
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.